<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366093">
  <stage>Registered</stage>
  <submitdate>1/04/2014</submitdate>
  <approvaldate>16/05/2014</approvaldate>
  <actrnumber>ACTRN12614000522617</actrnumber>
  <trial_identification>
    <studytitle>Assessment of three e-cigarette nicotine blends,
when used by current smokers.
</studytitle>
    <scientifictitle>A Four-Way Crossover Study Comparing Nicotine Pharmacokinetics and Exhaled Carbon Monoxide Levels of a Traditional Tobacco Cigarette and Three Nicotine-Based eLiquid Blends Delivered via e-Cigarette, Following Single Use in Healthy Male Smokers.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Smoking</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study compares three commercially available eliquid blends with a standard cigarette. 

For each of the 3 blends, nicotine concentration is the same, 2%(w/w), 34uL = 0.8 mg nicotine. Typical e-liquid use is 17-51 uL over 10 inhalations (20 - 60 mg delta weight observed when weighing the e-cig before and after use). This  represents between 0.4 - 1.2 mg nicotine per series of 10 inhalations.

In particular, researchers want to know:
	How much nicotine gets into the blood with each product?
	How quickly does nicotine reach maximum levels in the blood with each product?
	How much does breath CO increase after using each product?

Each participant will smoke one standard tobacco cigarette and 3 e-cigarettes in a randomised order 90 minutes apart</interventions>
    <comparator>one standard tobacco cigarette containing approximately 20.5mg of nicotine</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>This will give the company important information about nicotine levels of the three eblends compared to traditional cigarettes, which will help further product development.
The concentration of nicotine entering the blood will be measured for each product using multiple blood samples over time. </outcome>
      <timepoint>Blood samples will be taken before inhaling and at 10 timepoints from 0 to 30 minutes
</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The amount of carbon monoxide (CO) in exhaled air will be measured for each product using a validated CO measuring device</outcome>
      <timepoint>CO measurement will be taken 1 minute prior to inhalation and at 30 minutes after inhalation commenced.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>none</outcome>
      <timepoint>none</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Smoke at least 5 cigarettes per day. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Impaired lung function</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants will be allocated a treatment sequence in an allocation concealment manner with allocation determined by "off-site" personnel</concealment>
    <sequence>computerised sequence randomisation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Bio-equivalence</endpoint>
    <statisticalmethods>The number of participants in this exploratory crossover over study was determined by the logistics. Minimal data is available on the pharmacokinetics of nicotine from e-cigarettes
Analysis of variance will be applied to the log transformed primary pk parameters</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>19/05/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>30/06/2014</anticipatedenddate>
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ploom</primarysponsorname>
    <primarysponsoraddress>660 Alabama Street, Second Floor, San Francisco, CA 94110 , USA</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Ploom</fundingname>
      <fundingaddress>660 Alabama Street, Second Floor, San Francisco, CA 94110 , USA</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Measuring nicotine levels in blood following smoking tobacco and e-cigarettes</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern B Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
PO Box 5013
Wellington 6145
</ethicaddress>
      <ethicapprovaldate>7/04/2014</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>20/03/2014</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Chris Wynne</name>
      <address>Christchurch Clinical Studies Trust Ltd
31 Tuam Street
Christchurch 8011</address>
      <phone>+64 3 372 9477</phone>
      <fax>+64 3 372 9478</fax>
      <email>chris@ccst.co.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Chris Wynne</name>
      <address>Christchurch Clinical Studies Trust Ltd
31 Tuam Street
Christchurch 8011</address>
      <phone>+64 3 372 9477</phone>
      <fax>+64 3 372 9478</fax>
      <email>chris@ccst.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Chris Wynne</name>
      <address>Christchurch Clinical Studies Trust Ltd
31 Tuam Street
Christchurch 8011</address>
      <phone>+64 3 372 9477</phone>
      <fax>+64 3 372 9478</fax>
      <email>chris@ccst.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Chris Wynne</name>
      <address>Christchurch Clinical Studies Trust Ltd
31 Tuam Street
Christchurch 8011</address>
      <phone>+64 3 372 9477</phone>
      <fax>+64 3 372 9478</fax>
      <email>chris@ccst.co.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>